In our plasma proteomics and immunoassays, for the first time, we identified plasma FCGR3A and haptoglobin as novel biomarkers that may be used to differentiate MIAC/IAI from non-MIAC/IAI patients complicated by PPROM. This evidence concerns the gene FCGR3A and preterm premature rupture of the membranes.